While Amgen Sees Success For Two Growth Drivers, Headwinds Remain
Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market
Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.
You may also be interested in...
Amgen Is Still ‘A Biotech At Heart’
Head of Amgen’s inflammation business, Kave Niksefat, gives insight into how the 40-year-old biotech maintains its culture of innovation and avoids falling into the “trap” of bureaucracy.
Amgen’s Sotorasib Updates Raise New Questions For KRAS Program
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.
Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody
Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.